Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK2 | P53671 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.46 |
| ▸ | JAK1 | P23458 | 4/20 | 0.43 |
| ▸ | JAK2 | O60674 | 3/20 | 0.43 |
| ▸ | TYK2 | P29597 | 3/20 | 0.43 |
| ▸ | JAK3 | P52333 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28382203 | 0.86 | FASN (0.40) | LIMK2BRD4 | |
| SCHEMBL19639671 | 0.86 | BRD4 (0.51) | GPR119JAK1JAK2TYK2JAK3 | |
| SCHEMBL17749019 | 0.85 | BRD4 (0.54) | LIMK2GPR119JAK1JAK2TYK2 | |
| SCHEMBL17753568 | 0.83 | BRD4 (0.40) | JAK1JAK2TYK2JAK3KDM4E | |
| SCHEMBL19639663 | 0.81 | KDM4E (0.46) | GPR119JAK1JAK2TYK2JAK3 | |
| SCHEMBL17754080 | 0.78 | JAK2 (0.45) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL22554120 | 0.72 | LIMK2 (0.63) | LIMK2GPR119KDM4EPKM | |
| SCHEMBL17748965 | 0.72 | JAK1 (0.41) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL16616925 | 0.71 | GPR119 (0.65) | LIMK2GPR119KDM4EPKM | |
| SCHEMBL16625205 | 0.70 | LIMK2 (0.51) | LIMK2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| EP-3218376-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | Genentech, Inc. (US) | 2017-09-20 | — | — | EP | disclosed |
| WO-2016077375-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | BRD4, BRDT, BRD3 | LIMK2 2461/4885GPR119 988/4885JAK1 169/4885 |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | LIMK2 2461/4885GPR119 988/4885JAK1 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.